BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026

Shots: P-III trial of survodutide (3.6 or 6mg, QW) in 755 pts, met both co-1EP using treatment-regimen & efficacy estimands. At Wk. 76, weight loss reached up to an average of 13.1% vs 3.1% with PBO, while up to 79.3% vs 32.7% pts achieved ≥5% weight loss (efficacy estimand) In 2EPs, trial showed reduced HbA1c by ~1.21% vs 0.03% from 7.4% at baseline & waist circumference by 11.1 vs 3.5cm. It also improved fasting glucose, HOMA-IR & HOMA-β, with ~29.5% achieving normoglycemia vs 4% (efficacy estimand); published in The NEJM Additional SYNCHRONIZE-1 sub-study data in 75 adults with obesity without T2D were presented. BI expects SYNCHRONIZE-CVOT results later this year & has launched P-III (SYNCHRONIZE-T2D) to assess survodutide’s glycemic-control effects in T2D adults Ref: Globenewswire  |   Image: Boehringer Ingelheim   |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026 appeared first on PharmaShots.